P.fizer Inc.’s bivalent vaccine for COVID-19 has received emergency approval for use as a booster in some infants.
According to the U.S. Food and Drug Administration, children between the ages of 6 months and 4 years can receive Pfizer-Biontech SE at least 2 months after completing their first series of vaccines. Said Tuesday.
According to the FDA, children who have already received the bivalent vaccines from Pfizer and BioNTech are well protected from the most serious complications of COVID-19 and are not approved to receive the injections again.
This approval closes the vaccination gap for infants who were able to receive three consecutive monovalent Pfizer injections but were then ineligible for the company’s bivalent booster. The bivalent shot is designed to protect against two of her Omicron variants called BA.4 and BA.5.
start from December, the FDA has allowed infants and children to receive the bivalent vaccine as the third dose in the first series of COVID vaccinations. The FDA also approved Moderna Inc.’s bivalent mRNA vaccine for use in this age group.
Booster uptake rates have declined across all age groups, with only 16% of Americans taking the latest Omicron-targeted shot.
Other must-read articles from TIME
